Every 424B that Nano-X Imaging Ltd. (NNOX) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow NNOX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full NNOX filings page.
Nano-X Imaging Ltd has priced a registered direct offering to a single institutional investor comprising 3,700,000 ordinary shares, 4,300,000 pre-funded warrants and 8,000,000 ordinary warrants, for $8,000,000 in gross proceeds. Each share unit is priced at $1.00 and each pre-funded unit at $0.9999.
The company expects net proceeds of $7.6 million, excluding any warrant exercises, to be used for working capital and general corporate purposes. Ordinary shares outstanding will rise from 70,588,638 to 78,588,638 assuming full exercise of pre-funded warrants and no exercise of ordinary warrants, representing meaningful dilution.
Management discloses substantial doubt about the company’s ability to continue as a going concern, with an accumulated deficit of $463 million as of March 31, 2026 and dependence on additional financing. An impairment assessment of assets and goodwill is underway and may materially affect final financial results.
NANO-X Imaging Ltd. is registering an at-the-market offering of up to $53,900,000 of ordinary shares under its $100,000,000 shelf, to be sold from time to time through Cantor Fitzgerald & Co. and Mizuho Securities USA LLC as agents, for up to a 3% commission.
Based on a July 21, 2026 price of $1.08 per share, total shares outstanding could reach up to 119,508,190, subject to the current limit of 100,000,000 authorized ordinary shares, which may constrain full use of the ATM unless shareholders approve an increase. Net proceeds are intended for research and development, manufacturing activities, and general corporate purposes.
The company reports an accumulated deficit of $463 million as of March 31, 2026 and states that existing cash is not sufficient to support operations for at least one year, raising substantial doubt about its ability to continue as a going concern, making this capital-raising facility important to its liquidity plans.
Nano-X Imaging Ltd is issuing 3,826,530 ordinary shares in a registered direct offering to a single institutional investor at $3.92 per share, raising gross proceeds of about $15.0 million. After placement agent fees and expenses, the company expects net proceeds of approximately $14.2 million, which it plans to use for general working capital and corporate purposes.
The offering implies an immediate dilution of about $2.35 per share to the new investor, based on an as adjusted net tangible book value of $1.57 per share as of September 30, 2025. As context, there were 65,382,892 ordinary shares outstanding as of September 30, 2025, so this deal modestly increases the share count. Nanox also highlights recent milestones, including expanded FDA clearances, a CE mark in Europe for its Nanox.ARC system, and a proposed acquisition of VHC IT for up to $800,000 to support U.S. deployment of its AI imaging solutions.